Regulatory T cells (Treg) can regulate alloantigens and may counteract chronic lung allograft dysfunction (CLAD) in lung transplantation. We analyzed Treg in peripheral blood prospectively and correlated percentages of subpopulations with the incidence of CLAD at 2 years. Among lung-transplanted patients between January 2009 and July 2011, only patients with sufficient Treg measurements were included into the study. Tregs were measured immediately before lung transplantation, at 3 weeks and 3, 6, 12, and 24 months after transplantation and were defined as CD4 + CD25 high T cells and further analyzed for CTLA4, CD127, FoxP3, and IL-2 expressions. Between January 2009 and July 2011, 264 patients were transplanted at our institution. Among the 138 (52%) patients included into the study, 31 (22%) developed CLAD within 2 years after transplantation. As soon as 3 weeks after lung transplantation, a statistically significant positive association was detected between Treg frequencies and later absence of CLAD. At the multivariate analysis, increasing frequencies of CD4  + CD25  high CD127   low   ,  CD4  + CD25  high FoxP3  + and CD4   +   CD25 high IL-2 + T cells at 3 weeks after lung transplantation emerged as protective factors against development of CLAD at 2 years. In conclusion, higher frequencies of specific Treg subpopulations early after lung transplantation are protective against CLAD development.
Abbreviations: AUC, area under the curve; BALF, bronchoalveolar lavage fluid; BOS, bronchiolitis obliterans syndrome; CD, cluster of differentiation; CI, confidence interval; CLAD, chronic lung allograft dysfunction; ECMO, extracorporeal membrane oxygenation; ECP, extracorporeal photopheresis; eDSA, early anti-HLA donor-specific antibodies;
Introduction
Long-term outcomes following lung transplantation are impaired due to the development of chronic lung allograft dysfunction (CLAD) (1, 2) . The incidence of CLAD after lung transplantation has been reported to range between 45% and 75% after 5 years (3).
CLAD is aggravated by multiple nonimmune factors, but is essentially caused by alloantigen priming of the recipient's adaptive immune system that is apparently not sufficiently suppressed by pharmacologic immune suppression to prevent the slow progress of this chronic destruction of the graft. The adaptive immune system, though, also comprises, besides effector T and B cells encoding rejection, antigen-specific suppressor T cells counteracting those effector immune responses. A specific subset of naturally occurring CD4 + (cluster of differentiation) suppressor T cells with constitutive expression of the IL-2 receptor achain (CD25) has been termed regulatory T cells (Treg) (4) . These Treg constitute 3-10% of the naive peripheral CD4 + T cell pool in humans and play an important role in the induction and maintenance of immunological tolerance to auto-and alloantigens (5) . Treg are especially enriched in the CD4 + CD25 high population (6, 7) and may express the functionally important cytotoxic T lymphocyte-associated antigen 4 (CTLA-4, i.e. CD152) (8, 9) , constitutively express the intracellular transcription factor FoxP3 (10, 11) and maybe CD127 low (12, 13) . Previously, we have shown in a small cohort that these Treg subsets measured in peripheral blood early after lung transplantation are interestingly correlated with early spirometric findings in the respective recipients (14) .
Here, we hypothesize that an early pro-regulatory phenotype in peripheral blood as defined by higher frequencies of important Treg subsets at 3 weeks after lung transplantation may predict later freedom from CLAD development.
Methods

Study population and clinical management of lung transplant recipients
A prospective study was designed in a single university center to evaluate the impact of Tregs on early (at 2 years) development of CLAD in lung transplantation. All patients who underwent lung transplantation between January 2009 and July 2011 were considered eligible to become enrolled in the study. According to the study protocol, peripheral blood Tregs were measured immediately before lung transplantation, at 3 weeks and 3, 6, 12, and 24 months after transplantation. Only those patients in whom measurements of Tregs were performed were included into the study. The remaining patients, who did not undergo Treg measurements, for lack of informed consent or in-hospital mortality, were excluded from the study (Figure 1 ).
In-hospital records and outpatient visits of both included and excluded patients were available and prospectively recorded in our center database for lung transplantation. Follow-up was 100% complete and ended on August 1, 2015. Mean follow-up was 44 AE 24 months (range 1-79 months).
Written informed consent for inclusion into the study was obtained from all recipients for drawing additional blood samples and monitoring clinical data.
The variables cytomegalovirus risk profile, postoperative and secondary extracorporeal membrane oxygenation (ECMO) support, and primary graft dysfunction (PGD) have been defined elsewhere (15, 16) . The variable CLAD included patients who developed either bronchiolitis obliterans syndrome (BOS) or restrictive allograft syndrome (RAS), and was defined by a decline of forced expiratory volume in 1 s (BOS) or forced vital capacity (RAS) less than 80% of the postoperative best values, which persisted for at least 3 weeks, despite treatment or without identifying a clear cause (2, (17) (18) (19) . Early anti-HLA donor-specific antibodies (eDSA) were defined as DSA, which were detected during initial hospitalization after lung transplantation. At our institution, eDSA are regularly controlled during initial hospital stay. However, at follow-up, eDSA are controlled only in patients at risk (20) . Infection occurring at follow-up after the initial hospital stay for transplantation was defined as a bacterial, fungal, or viral infection that needed hospitalization and treatment. Two distinct acute rejection entities were defined for analysis, since not all assumed and treated episodes of acute rejection were biopsied and confirmed in histology. First, all steroidresponsive deteriorations in lung function after exclusion of other causes were defined as "pulsed steroid therapies" (20) . Pulsed steroid therapy consisted of 500-1000 mg methylprednisolone/day for 3 days. Second, biopsy-diagnosed acute rejections were defined according to the International Society for Heart and Lung Transplantation guidelines (21) .
The immunosuppressive therapy used at our institution during the study period is reported in the supplemental material.
Isolation of PBMC and flow cytometric analyses
Heparinized blood samples were drawn immediately before and 3 weeks, 3, 6, 12, and 24 months after transplantation. Peripheral blood mononuclear cells (PBMC) were isolated by Ficoll-density-gradient centrifugation, washed, and adjusted to 1 9 10 6 /mL per tube. The samples were stained with anti-human CD4-FITC, CD25-PE-Cy5, and CD3-PE, CD8-PE, CD19-PE, CD28-PE, CD45RA-PE, CD45RO-PE, CD69-PE, CD127-PE, and CD152 (CTLA-4)-PE (all from BD Pharmingen, San Diego, CA). For flow cytometric analysis of FoxP3, the cells were first stained with anti-human CD4-FITC and CD25-PE-Cy5, then washed and resuspended in 1 mL of cold Fixation/Permeabilization working solution (eBioscience, San Diego, CA), and incubated at 4°C for 30 min in the dark. After washing twice with permeabilization buffer (eBioscience), the cells were resuspended in permeabilization buffer, then anti-human FoxP3-PE (PCH101; eBioscience) was added, and samples were incubated at 4°C for 30 min in the dark. After staining and washing, cells were analyzed using a flow cytometer (BD FACS Canto II, Heidelberg, Germany) and FACS Diva 6.1.3 software. For the assessment of the Treg we used a method based on a multicolor analysis. In-hospital deaths, n = 21 (17%)
In-hospital deaths, n = 3 (2%) Figure 1 : Flowchart depicting the distribution and development of lung transplantation recipients included into the study and of those who were excluded.
Intracellular cytokine staining of PBMC PBMC were isolated as described above and resuspended in patients' own serum. RPMI 1640 medium was added at the same volume and the cells were stimulated with 25 ng/mL of phorbol-12-myristate-13-acetate (Sigma, St. Louis, MO), 1 lM of ionomycin (Sigma), and 10 lg/mL of brefeldin A (Sigma) for 4 h at 37°C. After washing with permeabilization buffer, they were resuspended in 100 lL of permeabilization buffer, and PE-conjugated antihuman interleukin (IL)-2, IL-4, IL-10, or c-interferon (IFN-c) was added, respectively. The cells were then incubated in the dark at room temperature for 20 min, washed twice, and analyzed per flow cytometry.
Statistical analyses
IBM SPSS 22.0 (Armonk, NY) and Graph Pad Prism 6 (GraphPad Software, La Jolla, CA) were used for the data analysis.
The primary endpoint was early (at 2 years) development of CLAD. Secondary endpoints were survival conditioned to initial hospital discharge after lung transplantation and overall freedom from CLAD, pulsed-steroid therapy, biopsy-confirmed acute rejection, and infection requiring hospitalization. Categorical and continuous variables were summarized as percentages and means AE standard deviation, respectively. The independent-samples Student's t-test or the nonparametric Mann-Whitney U-test for those variables where an equality of variance could not be assumed, and the chi-square test or the Fisher's exact test were used for group comparisons of continuous and categorical variables, respectively. Survival estimates along with freedom from endpoints were calculated by the product-limit method of Kaplan-Meier. Differences among groups were quantified using the log-rank test. Two-tailed p-values ≤0.05 were considered significant.
In order to account for the patients who were excluded from the study, patient characteristics as well as endpoints were compared among included and excluded patients. we previously showed to correlate with spirometry outcomes after lung transplantation (14) , on development of CLAD at 2 years was evaluated in two ways.
First, comparisons of data with repeated measurements (Treg at 3 weeks, 3 months, 6 months, 12 months, and 24 months) were performed using repeated-measurement analysis of variance (ANOVA), among the included patients who were CLAD-free and those who showed CLAD at 2 years follow-up. Frequencies of the Treg subpopulations were also stratified according to use at follow-up of everolimus, cyclosporine, extracorporeal photopheresis (ECP) (22) , and immunomodulatory therapy with macrolides for neutrophilic reversible graft dysfunction (23) , and to the presence of BOS or RAS and the need for pulsed steroid therapy for presumed acute rejection. Results of these subanalyses were reported as supplemental materials (Tables S3-S8) .
Second, multivariate analysis, using a binary forward stepwise logistic regression model, was used to identify independent risk factors for development of CLAD at 2 years. Results were controlled performing a backward logistic regression analysis. Model calibration and validity were evaluated using the Hosmer-Lemeshow (H-L) test for goodness of fit. Model accuracy was evaluated through the receiver operating characteristic (ROC) curves, which report the area under the curve (AUC) for each predictor obtained at the multivariate analysis.
In addition, CLAD was also considered a time-dependent variable and a Cox multivariate regression analysis was used to identify the risk factors for chronic rejection over the whole study period. Results were obtained and controlled by performing a forward and backward logistic regression analysis.
The variables, which were analyzed to identify univariate and multivariate associations with CLAD, are reported in Tables 2-4 . In addition, the variables lung infection requiring hospitalization, need for pulsed steroid therapy at follow-up, and biopsy-confirmed rejections were included in the univariate and multivariate models.
Finally, only frequencies of Treg subpopulations at 3 weeks were included in the models, because the protective effects of Tregs were observed as early as 3 weeks and persisted at 3, 6, 12, and 24 months and Treg values were available for all included patients.
Results
Included versus excluded patients
Between January 2009 and July 2011, 264 consecutive patients underwent lung transplantation at our institution. Among these patients, 138 (52%) patients underwent Treg measurements at 3 weeks and 3, 6, 12, and 24 months after transplantation and were included into the study. The remaining 126 (48%) patients who did not undergo Treg measurements were excluded from the study (Figure 1 ).
Excluded patients showed a higher preoperative risk profile than included patients, since they more often underwent transplantation for primary pulmonary hypertension and required pretransplant intensive care treatment and ECMO support (Table S1 , supplemental material). They also showed a higher prevalence of postoperative complications than included patients, such as evidence of primary graft dysfunction, need for pulsed steroid therapy for presumed rejection during initial hospital stay, and in-hospital mortality (Table S2 , supplemental material).
Instead, outcomes after hospital discharge did not differ between included and excluded patients ( Table 1) . Incidence of CLAD at 2 years ( Figure 1 ) as well as overall freedom from CLAD (Table 1 and Figure 2 ) did not differ between included and excluded patients (p = 0.32 and p = 0.22, respectively). Survival conditioned to hospital discharge as well as freedom from pulsed steroid therapies, biopsy-confirmed acute rejections, and infections did not differ between included and excluded patients (p = 0.35, p = 0.20, p = 0.36, and p = 0.26, respectively, Table 1 ).
Among the 138 patients who were included in the study, 31 patients developed CLAD at 2 years follow-up (Figure 1 Tables 2 and 3 .
Frequency of CD4 + CD25 high T cells and their subpopulations in peripheral blood
In the 138 patients who were included into the study, peripheral whole blood samples were drawn immediately before transplantation and 3 weeks, 3, 6, 12, and 24 months after transplantation (Table 4) . Among the surviving patients at each time point, Treg measurements were available for 138 (100%) patients at 3 weeks, for 122 (91%) patients at 3 months, for 115 (88%) patients at 6 months, 110 (87%) patients at 1 year, and 87 (77%) patients at 2 years.
PBMC from these patients were isolated and stained for CD4 and CD25. For fluorescence-activated cell sorting (FACS) analysis, the gate was set on CD4 + CD25 high cells in the lymphocyte gate, and percentages of CD4 + CD25
high cells compared between the CLAD-free course and the CLAD course groups. Although percentages were slightly higher in the CLAD-free course group at some points of time, differences were not statistically significant (p = 0.5, ANOVA for repeated measurements; Figure 3A ).
Instead, CD4 + CD25
high CD127 low cells in the lymphocyte gate did not differ between stable and CLAD course group patients before transplantation, but at every point of time measured after transplantation ( Figure 3B , Table 4 ). CD4 + CD25 high FoxP3 + cells in the lymphocyte gate behaved similarly, showed a small but not significant difference before transplantation that widened markedly after transplantation ( Figure 3C , Table 4 transplantation (p = 0.6), but markedly differed at any time point posttransplantation ( Figure 3D , Table 4 ). The percentage of IL-2 + cells in the CD4 + CD25 high population within the lymphocyte gate was different before transplantation (p = 0.03), but interestingly this difference became more pronounced after transplantation (Figure 3E , Table 4 ). Treg frequencies did not differ after stratification according to addition/switch to everolimus (Table S3 , supplemental material), to tacrolimus use (Table S4 , supplemental material) and ECP use (Table S5 , supplemental material), presence of BOS or RAS (Table S6 , supplemental material), macrolide therapy (Table S7 , supplemental material), and to pulsed steroid therapy (Table S8 , supplemental material), within 2 years after lung transplantation. Thirteen patients (CLAD-free patients, n = 11; CLAD patients, n = 2) were switched to everolimus at a mean of 17 AE 16 months (range, 1-49 months) after transplantation. ECP and macrolide therapies were initiated at a mean of 21 AE 5 months (range 14-33 months) and 17 AE 6 months (range 6-30 months), after transplantation.
We also compared the absolute number of lymphocytes in peripheral blood between both groups within the first 2 years after lung transplantation and no significant differences emerged (p = 0.74, Figure 3F ).
Using multicolor FACS analysis and staining single samples for CD4, CD25, CD127, FoxP3, and CTLA4 mAbs, we show in representative samples a large overlap of the four Treg subpopulations assessed in this study ( Figure 3G ).
Risk factors for CLAD at 2 years and over the whole study period The univariate and multivariate logistic regression analysis for early CLAD development at 2 years is reported in (Table 5) , only the need for pulsed steroid therapy for presumed rejection at follow-up significantly predicted CLAD (AUC 0.61, 95% CI, 0.52-0.70, p = 0.03).
Discussion
This study shows that increasing frequencies of peripheral blood Treg (CD4 + CD25 high ) subpopulations expressing CD127 low , FoxP3 + , and IL-2 + had an independent protective role against development of early (at 2 years) CLAD. The statistical model thus obtained could further be used to predict CLAD development at 2 years. The Cox logistic regression analysis over the whole study period confirmed the results obtained by the logistic regression analysis at 2 years. Moreover, while a relationship between lower Treg counts in FACS assays and CLAD had already been demonstrated at the time of established disease by other authors as detailed below, our study shows this relationship from blood samples drawn as early as 3 weeks after transplantation in a sizeable patient cohort. Treg frequencies were not influenced by the addition or switch to everolimus, immunosuppressive therapy with tacrolimus, ECP use, immunomodulatory therapy with macrolides, CLAD phenotype (BOS vs. RAS), or pulsed steroid therapy at follow-up for presumed acute rejection.
Previously, Meloni et al had shown in a small cohort of lung transplantation recipients greater than 3 years posttransplantation that CD4 + CD25 + putative Tregs in peripheral blood were decreased in those with BOS (n = 11) as compared to those in stable clinical condition (n = 10) (24). The correlation was only made in patients with established BOS, thus no prediction was possible. In 2010, Gregson et al published a study from 47 lung transplant recipients, 13 of whom eventually developing BOS, showing that a specific Treg subset, CCR7 + CD3 + CD4 + CD25 high FoxP3 + CD45RA À lymphocytes, in bronchoalveolar lavage fluid (BALF) are negatively correlated with later occurrence of BOS (25) . This was the first study to demonstrate a correlation of Treg measured early after transplantation and later BOS development. In line with our findings (Figure 3A ), Gregson and colleagues could not show this correlation for total CD4 + CD25 + T cells, but only for a further defined subpopulation. In that study, however, only Treg in BALF were considered, a sample requiring a bronchoscopy, being not only more difficult to conduct, but also potentially leading to inconsistent sample quality, thus lowering the patient number for eventual analysis to n = 23 without and n = 10 with BOS in their study. In 2010, Bhorade et al published their study on the prediction of BOS by analyzing Treg in BALF in a small cohort of 20 patients (26) . Despite the low patient number in this study, the authors succeeded in calculating a "Treg threshold," defined as CD4 + FoxP3 + cells in BALF, distinguishing patients with or without risk for BOS development. However, they did not show any correlation in peripheral blood.
In contrast, our study includes 138 patients, 31 of whom developed CLAD within 2 years. Treg were measured in peripheral blood that is more straightforward to obtain than BALF, and the points of time when blood samples were drawn were predefined at 3 weeks, 3 months, 6 months, 12 months, and 24 months. Thus, all patients have repetitive sampling, enabling the study of Treg counts over time. However, the 2-year threshold was chosen arbitrarily to allow for comparing the stable and CLAD course groups at similar risk levels for all patients in the study. In addition, evidence from Finlen Copeland et al that patients with early onset CLAD did worse than Values are expressed as mean AE standard deviation. CLAD, chronic lung allograft dysfunction.
patients with late onset CLAD supports the decision of evaluating the impact of Treg frequencies on early CLAD development in our study (27) .
The following mechanisms can explain the relationship among early (3 weeks) Treg frequencies and later CLAD prevention. In fact, alloantigen recognition and T cell priming usually takes place within the first days post lung transplant, with both effector and regulatory T cells being primed in parallel. This priming has progressed far enough at 7 days that cellular acute rejection takes place in some patients. Thus, T cell priming is more or less finished within the first 1 or 2 weeks posttransplant. In the setting of nonimmunosuppressed hosts, the effector arm succeeds and rejection takes place. However, it is known that certain conditions favor priming of regulatory T cells over effector T cells, for example, in the absence of unspecific inflammation but in the presence of a high donor antigen load. Hence, patients with severe PGD have more early inflammation possibly triggering effector priming and later CLAD. Patients without PGD and without early infections have low inflammatory burdens and may prime more
Tregs. In recipients who had undergone more Treg priming early after transplant, subclinical T cell-mediated damage to the lung allograft might be suppressed by Treg, hence CLAD would be prevented (5,28).
There has been endless debate on the most specific markers to be used to define Treg, hence there still is no definitive marker. Instead, multiple markers remain in use that are enriched, or highly enriched, in Treg. CD127 low expression is known to be highly enriched in regulatory CD4+CD25+ T cells and might well be the most specific marker known and used to date (29) . FoxP3 has been known to be rather specific for both naturally occurring and induced Treg for the last 15 years (4). However, it is also expressed transiently in activated effector T cells, although with less intensity than in Treg (30) . Our data support the role of FoxP3, given its good fit with the CD127 low subpopulation results and overlap in multicolor stainings. CD152 (CTLA-4) is not specific for Treg, but is an important functional marker since it mediates costimulation blockade, an important proregulatory pathway used by Treg (31, 32) . Its rather unspecific nature as a Treg marker is supported by our results, which showed no statistically significant correlation with CLAD incidence. IL-2 is even less specific for Treg. Contrarily, some investigators even proposed that Treg do not express IL-2 at all (13). However, there is debate on this and there have been other studies recently, showing that Treg even depend on (low level) IL-2, as they are known to also depend on low levels of IFN-c expression (33) . The fact that IL-2 is enriched in CD4 + CD25 high T cells that are more frequent in lung transplant recipients with a stable (non-CLAD) course is a novel finding.
In this study, we have not tested for regulatory function of the Treg populations. We did, however, perform parallel in vivo studies on Treg function from a small subgroup of the lung transplantation recipients reported here (n = 25) using a humanized mouse model (34, 35) . In that latter humanized mouse model, leukocytes from clinical lung transplant recipients were transferred into immune-deficient mice bearing aortic human arterial vascularized grafts (from the lung donors). In some experiments, human CD4 + CD25 + Treg from the respective lung recipients were isolated, enriched, and adoptively cotransferred. These Treg had very strong suppressive function on the development of transplant arteriosclerosis, essentially abrogating the condition. We thus propagate that the CD4 + CD25 high T cells studied in our routine lung recipient cohort in fact have strong regulatory function that is, according to our herein reported data, especially enriched in the CD4 + CD25 high CD127 low subpopulation.
The ultimate goal with respect to the finding of the importance of higher Treg subset frequencies early after lung transplantation would be to develop strategies to augment the Treg frequency, potentially reducing the proportion of recipients at risk to develop CLAD. We already have successfully achieved these in small (29) and large animal models (36,37). Moreover, based on the results of this study, we actually perform Treg measurements at 3 weeks in all eligible patients undergoing lung transplantation at our institution. Our next target is to prospectively create a score based on Tregs levels at 3 weeks to predict the overall BOS risk, not only at 2 years.
Study Limitations
There are several limitations to this study. Although results are based on a still numerous population, almost 50% of the patients transplanted between January 2009 and July 2011 had to be excluded from the study due to lack of Tregs measurements. However, excluded patients did not show any difference in CLAD incidence and survival in comparison to included patients. Only Tregs frequencies at 3 weeks were included in the multivariate model for two reasons. First, Treg frequencies were available for all patients at this time point. Second, as reported in Figure 3 , the protective effect of Tregs against CLAD, which emerged as early as 3 weeks, persisted also thereafter, at 3, 6, 12, and 24 months. Moreover, Tregs were not measured specifically at the time of first CLAD diagnosis. As such, we are not able to strictly perform an analysis with CLAD diagnosis as time 0.
At follow-up, Tregs frequencies could have been influenced by changes in immunosuppressive therapies, such as the addition/switch to everolimus, cyclosporine versus tacrolimus use, or by additional procedures and therapies, such as ECP and immunomodulatory therapy with macrolides for neutrophilic reversible graft dysfunction. However, all these therapies and procedures were added well after the third week after transplantation, at which point we started to measure Tregs and where the protective effects of Tregs were first evidenced.
Finally, data on presence of lymphocytic bronchiolitis and DSA at follow-up were not available. In this last case, at our institution, DSA are controlled only in patients at risk after initial discharge after lung transplantation (20) .
Conclusions
Increasing frequency of CD127 low , FoxP3 + , and IL-2 + cells within the CD4 + CD25 high population as early as 3 weeks after transplantation is associated with reduced incidence of CLAD at 2 years. Thus, these results may be used for creating a score to predict the overall CLAD risk. Finally, autologous expanded Tregs may be used for cellular therapies in lung transplantation in future. 
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